Babesia bigemina (B. bigemina)

Babesia bigemina is a tick-borne protozoan parasite that serves as a major causative agent of bovine babesiosis, a disease characterized by high fever and severe hemolytic anemia in cattle [1, 2]. As a member of the phylum Apicomplexa, it primarily infects and replicates within host erythrocytes, leading to significant economic losses in the livestock industry worldwide [2, 11]. The parasite is transmitted by ixodid ticks, particularly those of the genus Rhipicephalus, which inject sporozoites into the host during feeding [2, 11]. Within the host, B. bigemina utilizes various molecular mechanisms for cell invasion and metabolic survival, including the use of lactate dehydrogenase for energy production and apical membrane antigens for host cell attachment [3, 7]. Current therapeutic interventions rely on babesicidal drugs such as diminazene aceturate and imidocarb dipropionate, which target the parasite's DNA synthesis and mitochondrial function [3, 12]. However, challenges such as host toxicity, drug residues in animal products, and the emergence of resistant strains have driven research into novel molecular targets and vaccines [4, 12]. Understanding the molecular biology of B. bigemina is crucial for developing more effective and safer control measures against this devastating veterinary pathogen.

Other names

Bovine babesiosis parasiteTexas fever parasitePiroplasma bigeminumBabesia bigeminum

Drugs targeting Babesia bigemina typically act by inhibiting DNA synthesis, interfering with polyamine metabolism, or disrupting mitochondrial electron transport and glycolytic enzymes like lactate dehydrogenase [3, 12, 13].